| Science/Technology
|
[
Science/Technology ] [ Main Menu ] |
|
|
|
7046 |
|
|
Date: June 23, 2021 at 07:08:21
From: Akira, [DNS_Address]
Subject: clinicaltrials.gov.. Study: Ivermectin in Adults w/Severe COVID-19 |
URL: https://clinicaltrials.gov/ct2/show/NCT04602507 |
|
The study ended in March 2021. No results have been posted.
excerpts:
Ivermectin in Adults With Severe COVID-19.
Primary Purpose: Treatment
Official Title: Ivermectin in Adults With Severe COVID-19. Double-blind
Randomized Clinical Trial
Actual Study Start Date : December 7, 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021
Study Description
Go to sections
Brief Summary:
Since the onset of the disease, more than 40.5 million people have been
diagnosed with COVID-19 and nearly 1.2 million people have died (October
21, 2020). There is no complete understanding of the pathogenesis of
SARS-CoV-2 infection and to this day there is no specific therapy or vaccine
available. Thus, patient care is based on symptomatic therapy and treatment
of complications.
Ivermectin has been used for more than 30 years for the treatment of
several diseases. More than one million doses of the drug are administered
daily, particularly in low- and middle-income countries. Due to the low
prevalence of adverse events with the use of this drug, ivermectin is
considered to have a good safety profile and its potential benefit in other
diseases is currently under investigation.
An in vitro study of ivermectin in SARS-CoV-2 in Australia showed a
significant reduction of viral load in infected cells. Subsequently, a
descriptive study of 704 critical patients with COVID-19 showed a reduction
in mortality, hospitalization, and intensive care unit length-of-stay in those
patients who received the drug. Unfortunately, this study was withdrawn by
its authors, leaving more questions than answers.
Some countries in Latin America have authorized its use for the
management of patients with COVID-19 even in the absence of solid
evidence, and several other countries are conducting clinical trials to
evaluate its efficacy for the treatment of moderate and severe disease.
Since there is no specific treatment for COVID-19 and the therapeutic
options are scarce, the researchers believe it is completely plausible, urgent,
and necessary to evaluate if ivermectin use reduces the risk of admission to
an intensive care unit (ICU) in hospitalized adults with severe COVID-19. The
proposal is a randomized, double-blind clinical trial, conducted at CES
Clinic, Medellin-Colombia. The investigators will randomize 100 patients
with severe, non-critical illness, into two groups, one group will receive
ivermectin in addition to standard management and the other group will
receive placebo plus standard management. Clinical outcomes to evaluate
will be ICU admission, need for mechanical ventilation, length of hospital
stay, days in the ICU and mechanical ventilation, and finally, the incidence of
adverse events related to the intervention. The estimated time to complete
the study is approximately five months.
|
|
|
|
|
Responses:
[7047] [7048] [7057] [7056] [7058] [7059] [7054] |
|
7047 |
|
|
Date: June 23, 2021 at 07:11:34
From: Akira, [DNS_Address]
Subject: PubMed: Ivermectin treatment for Covid-19 |
URL: https://pubmed.ncbi.nlm.nih.gov/33278625/ |
|
A five-day course of ivermectin for the treatment of COVID-19 may reduce
the duration of illness
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic
agent, was found to inhibit severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-
controlled trial was conducted to determine the rapidity of viral clearance
and safety of ivermectin among adult SARS-CoV-2 patients. The trial
included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned
to one of three groups: oral ivermectin alone (12 mg once daily for 5 days),
oral ivermectin in combination with doxycycline (12 mg ivermectin single
dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for
the next 4 days), and a placebo control group. Clinical symptoms of fever,
cough, and sore throat were comparable among the three groups.
Virological clearance was earlier in the 5-day ivermectin treatment arm
when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but
this was not the case for the ivermectin + doxycycline arm (11.5 days; p =
0.27). There were no severe adverse drug events recorded in the study. A 5-
day course of ivermectin was found to be safe and effective in treating adult
patients with mild COVID-19. Larger trials will be needed to confirm these
preliminary findings.
|
|
|
|
|
Responses:
[7048] [7057] [7056] [7058] [7059] [7054] |
|
7048 |
|
|
Date: June 24, 2021 at 12:51:17
From: ryan, [DNS_Address]
Subject: Re: PubMed: Ivermectin treatment for Covid-19 |
|
|
|
or it may kill them...jury is out...
|
|
|
|
|
Responses:
[7057] [7056] [7058] [7059] [7054] |
|
7057 |
|
|
Date: June 26, 2021 at 05:51:45
From: Akira, [DNS_Address]
Subject: proven safe - It's been in use for 3 decades... posted on health(NT) |
|
|
|
|
|
|
|
Responses:
None |
|
7056 |
|
|
Date: June 26, 2021 at 05:46:43
From: Akira, [DNS_Address]
Subject: Re: PubMed: Ivermectin treatment for Covid-19 |
|
|
|
|
|
|
|
Responses:
[7058] [7059] |
|
7058 |
|
|
Date: June 26, 2021 at 10:39:04
From: ryan, [DNS_Address]
Subject: Re: PubMed: Ivermectin treatment for Covid-19 |
|
|
|
|
|
|
|
Responses:
[7059] |
|
7059 |
|
|
Date: June 26, 2021 at 13:01:24
From: chatillon, [DNS_Address]
Subject: Re: PubMed: Ivermectin treatment for Covid-19 |
|
|
Dosage.
Of course.
Drinking too much water can kill you, too.
|
|
|
|
|
Responses:
None |
|
7054 |
|
|
Date: June 25, 2021 at 17:34:49
From: kay.so.or, [DNS_Address]
Subject: Re: PubMed: Ivermectin treatment for Covid-19 |
|
|
|
well I prefer the ivermectin ryan to the vax's...and anything can kill you....seeing so many 'leaving' this earth plane in so many ways!!....it is the time of 'changes/shift', in my opinion, and its darn hard and sad :-(
|
|
|
|
|
Responses:
None |
|
[
Science/Technology ] [ Main Menu ] |